This site is intended for U.S. healthcare professionals only.

ABOUT MDD

Depression can have a major impact on people's lives

Depression affects millions of people. Every patient is different and responds to treatment differently. For healthcare professionals seeking another option, FETZIMA® is approved to treat major depressive disorder in adults.

Depression affects many...

  • MDD is the #1 contributor to disability worldwide5
  • MDD is the most common mental illness in the U.S., affecting almost 16 million adults6,7

In many different ways...

  • MDD is a heterogeneous disease—every patient can present with different symptoms8
  • Persistent depressed mood or loss of interest are common defining features of MDD*8
  • Other symptoms are also persistent and vary by patient8
    • Insomnia or hypersomnia
    • Weight gain or weight loss; increase or decrease in appetite
    • Psychomotor agitation or psychomotor retardation
    • Fatigue or loss of energy
    • Feelings of worthlessness or excessive/inappropriate guilt
    • Diminished ability to think/concentrate or indecisiveness
    • Recurrent thoughts of death/suicide or suicide attempt
  • Diagnosis of MDD requires five (or more) of the symptoms listed above, must be present for at least 2 weeks, and represent a change from previous functioning. At least one of the symptoms is either depressed mood or loss of interest or pleasure.8

Unmet needs still exist


In an analysis from the 2006 U.S. National Health and Wellness Survey (NHWS)...

Nearly

70%

of patients with MDD were nonresponders or partial responders9

According to results from the National Comorbidity Survey Replication (NCS-R)...

Nearly

90%

of MDD patients with depressive symptoms also reported moderate to very severe levels of functional impairment10

INDICATION and USAGE

FETZIMA (levomilnacipran) extended-release capsules is indicated for the treatment of Major Depressive Disorder (MDD) in adults.

FETZIMA is not approved for the management of fibromyalgia, and its efficacy and safety have not been established for that use.

IMPORTANT SAFETY INFORMATION

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

Antidepressants increased the risk of suicidal thoughts and behavior in pediatric, and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors.

FETZIMA is not approved for use in pediatric patients.

Contraindications

Warnings and Precautions
Adverse Reactions

Please also see the full Prescribing Information, including Boxed Warning.


IMPORTANT SAFETY INFORMATION

More

INDICATION and USAGE

FETZIMA (levomilnacipran) extended-release capsules is indicated for the treatment of Major Depressive Disorder (MDD) in adults.

FETZIMA is not approved for the management of fibromyalgia, and its efficacy and safety have not been established for that use.

IMPORTANT SAFETY INFORMATION

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

Antidepressants increased the risk of suicidal thoughts and behavior in pediatric, and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors.

FETZIMA is not approved for use in pediatric patients.

Contraindications

  • FETZIMA is contraindicated in patients with a hypersensitivity to levomilnacipran, milnacipran HCl, or to any excipient in the formulation.
  • The use of MAOIs intended to treat psychiatric disorders with FETZIMA or within 7 days of stopping treatment with FETZIMA is contraindicated due to an increased risk of serotonin syndrome. The use of FETZIMA within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated.
    Starting FETZIMA in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated due to an increased risk of serotonin syndrome.
Warnings and Precautions
  • Suicidal Thoughts and Behavior in Adolescents and Young Adults: Monitor all antidepressant-treated patients for any indication for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy, and at times of dosage changes. Counsel family members or caregivers of patients to monitor for changes in behavior and to alert the healthcare provider. Consider changing the therapeutic regimen, including possibly discontinuing FETZIMA, in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.
  • Serotonin Syndrome: SSRIs and SNRIs, including FETZIMA, can precipitate serotonin syndrome, a potentially life-threatening condition. The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. John’s Wort) and with drugs that impair metabolism of serotonin, i.e., MAOIs. Symptoms of serotonin syndrome may include mental status changes (eg, agitation, hallucinations, delirium, and coma), autonomic instability (eg, tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (eg, tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms. If symptoms of serotonin syndrome occur, discontinue FETZIMA immediately and initiate supportive treatment. If concomitant use of FETZIMA with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms.
  • Elevated Blood Pressure: SNRIs, including FETZIMA, have been associated with increases in blood pressure. Blood pressure should be measured prior to initiating treatment and periodically throughout FETZIMA treatment. Pre-existing hypertension should be controlled before initiating treatment with FETZIMA. Use with caution in patients with pre-existing hypertension, cardiovascular, or cerebrovascular conditions that might be compromised by increases in blood pressure. Concomitant use of FETZIMA with drugs that increase blood pressure and heart rate has not been evaluated and such combinations should be used with caution. For patients who experience a sustained increase in blood pressure, discontinuation or other appropriate medical intervention should be considered.
  • Elevated Heart Rate: SNRIs, including FETZIMA, have been associated with an increase in heart rate. Heart rate should be measured prior to initiating treatment and periodically throughout FETZIMA treatment. Pre-existing tachyarrhythmias and other cardiac disease should be treated before starting therapy with FETZIMA. For patients who experience a sustained increase in heart rate, discontinuation or other appropriate medical intervention should be considered.
  • Increased Risk of Bleeding: Drugs that interfere with serotonin reuptake inhibition, including FETZIMA, may increase the risk of bleeding events. Concomitant use of aspirin, NSAIDs, warfarin, and other anticoagulants may add to this risk.
  • Angle-closure Glaucoma: Angle closure glaucoma has occurred in patients with untreated anatomically narrow angles treated with antidepressants. The pupillary dilation that occurs following use of many antidepressant drugs including FETZIMA may trigger an angle closure attack in a patient with anatomically narrow angles who does not have a patent iridectomy.
  • Urinary Hesitation or Retention: FETZIMA can affect urethral resistance. In clinical studies, urinary hesitation occurred in 4%, 5%, and 6% of FETZIMA-treated patients receiving doses of 40, 80, and 120 mg, respectively, compared to no patients in the placebo group. Caution is advised when using FETZIMA in patients prone to obstructive urinary disorders.
  • Activation of Mania/Hypomania: Symptoms of mania/hypomania were reported in 0.2% of FETZIMA-treated patients and 0.2% of placebo-treated patients in clinical studies. As with all antidepressants, FETZIMA should be used cautiously in patients with a history or family history of bipolar disorder, mania, or hypomania. Prior to initiating treatment with FETZIMA, patients should be adequately screened to determine if they are at risk for bipolar disorder. FETZIMA is not approved for use in treating bipolar depression.
  • Seizures: FETZIMA should be prescribed with caution in patients with a seizure disorder.
  • Discontinuation Syndrome: Discontinuation symptoms, some serious, have been reported with discontinuation of serotonergic antidepressants such as FETZIMA. Gradual dose reduction is recommended, instead of abrupt discontinuation, whenever possible. Monitor patients when discontinuing FETZIMA. If intolerable symptoms occur following a dose decrease or upon discontinuation of treatment, consider resuming the previously prescribed dose and decreasing the dose at a more gradual rate.
  • Hyponatremia: Advise patients that if they are treated with diuretics or are otherwise volume depleted, or are elderly, they may be at greater risk of developing hyponatremia while taking FETZIMA. Although no adverse events of hyponatremia resulting from FETZIMA treatment were reported in the clinical studies, hyponatremia has occurred as a result of treatment with SSRIs and SNRIs. FETZIMA should be discontinued in patients with symptomatic hyponatremia and appropriate medical intervention should be instituted.
  • Drug Interactions: Concomitant use of FETZIMA with strong CYP3A4 inhibitors increases levomilnacipran exposure. The dose of FETZIMA should not exceed 80 mg once daily when used with strong CYP3A4 inhibitors. Alcohol should be avoided while taking FETZIMA.
  • Pregnancy: Third trimester use may increase risk postpartum hemorrhage and may increase the risk of neonatal complications requiring prolonged hospitalizations, respiratory support, and tube feeding.
  • Lactation: Breastfeeding women should monitor infants for sedation, agitation, irritability, poor feeding, and poor weight gain and should seek medical care if they notice these signs.
Adverse Reactions
  • The most commonly observed adverse reactions in MDD patients treated with FETZIMA in placebo-controlled studies (incidence ≥5% and at least twice the rate of placebo) were: nausea (17% vs 6%), constipation (9% vs 3%), hyperhidrosis (9% vs 2%), heart rate increased (6% vs 1%), erectile dysfunction (6% vs 1%), tachycardia (6% vs 2%), vomiting (5% vs 1%), and palpitations (5% vs 1%).

Please also see the full Prescribing Information, including Boxed Warning.